Live Breaking News & Updates on Apelli Annual Report

Stay updated with breaking news from Apelli annual report. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Lissa Pavluk , Meredith Kaya , Fadi Fakhouri , Lydia Abad Franch , Caroline Baumal , Exchange Commission , Apellis Pharmaceuticals Inc , Sobi Investor Relations Team , European Renal Association , Exchange Commission On , National Institute Of Health , European Union , North America , Middle East , Forward Looking Statement , Private Securities Litigation Reform Act , Apelli Annual Report , Sobi Media , Genetics Home , Accessed November ,

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® $25.6 million for EMPAVELI® Anticipates CHMP opinion for pegcetacoplan. ....

United States , Philip Ferrone , Meredith Kaya , Lissa Pavluk , Cedric Francois , Exchange Commission On , Apellis Pharmaceuticals Inc , Advisory Committee On Immunization Practices , European Union , Exchange Commission , European Medicines Agency , Nocturnal Hemoglobinuria , Senior Convertible Notes , Safety Information , Retinal Detachments , Retinal Vascular Occlusion , Vascular Endothelial Growth Factor , Prescribing Information , Advisory Committee , Immunization Practices , Risk Evaluation , Mitigation Strategy , Infections Caused , Patient Safety Card , Private Securities Litigation Reform Act , Apelli Annual Report ,

Apellis Pharmaceuticals : First Quarter 2024 Earnings Presentation

Apellis Pharmaceuticals : First Quarter 2024 Earnings Presentation
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Exchange Commission On , Exchange Commission , Private Securities Litigation Reform Act , Apelli Annual Report ,

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Meredith Kaya , Lissa Pavluk , Committee For Medicinal Products Human Use , Apellis Pharmaceuticals Inc , European Medicines Agency , European Union , Exchange Commission On , Exchange Commission , Medicinal Products , Human Use , Private Securities Litigation Reform Act , Apelli Annual Report ,

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist P. ....

Union College , New York , United States , Meredith Kaya , Philip Ferrone , Lissa Pavluk , Caroline Baumal , American Society Of Retina Specialists , Apellis Pharmaceuticals Inc , Duke University Eye Center , Exchange Commission On , Exchange Commission , Harvard Medical School , Chief Medical Retina Advisor , American Society , Retina Specialists , Chief Medical Officer , Vitreoretinal Consultants , Harvard Medical , Associated Retinal Consultants , Royal Oak , Chief Resident , Duke University Eye , Safety Information , Retinal Detachments , Retinal Vascular Occlusion ,